San Diego’s Abreos Biosciences has raised $725,000 in a seed round of funding.

The round was led by Triton Technology Fund, a UCSD alumni-led venture capital fund focused on commercializing innovations by UC San Diego faculty, students and alumni.

Abreos, a health care company advancing technology for precision dosing of biologic drugs, intends to use the funds to accelerate their commercialization plan, expand their marketing and business development teams, and establish major clinical research partnerships in the U.S. and Europe.

Founded in 2013 at UC San Diego by Dr. Bradley Messmer (CEO) and Dr. Thomas Kipps, Abreos is developing point-of-care devices that monitor the levels of biologic drugs in patients for precision dose guidance.

With this capability, patients can ensure they are receiving and maintaining the right amount of these expensive medications.

The company has developed tests for the top biologic drugs used in autoimmune and neurology disorders, and cancer.